What is the recommended treatment for gonorrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Gonorrhea

Primary Recommended Treatment

The recommended treatment for uncomplicated gonorrhea is ceftriaxone 500 mg intramuscularly as a single dose, plus azithromycin 1 g orally as a single dose. 1, 2

This dual therapy approach addresses both gonorrhea and potential chlamydial co-infection (present in 40-50% of cases), while also helping to prevent the emergence of cephalosporin resistance. 1

Rationale for Dual Therapy

  • Combination therapy improves treatment efficacy and delays the emergence and spread of antimicrobial resistance by using two drugs with different mechanisms of action. 1
  • Azithromycin is strongly preferred over doxycycline due to the convenience and compliance advantages of single-dose therapy, and substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin. 1
  • If chlamydial infection has not been excluded by testing, concurrent treatment is mandatory. 2

Dosing Specifications

  • Ceftriaxone 500 mg IM achieves a 99.1% cure rate for uncomplicated urogenital and anorectal gonorrhea. 1
  • The 500 mg dose represents an update from the previous 250 mg recommendation, reflecting evolving resistance patterns. 2
  • Azithromycin 1 g orally provides effective single-dose chlamydia coverage. 1

Alternative Regimens (When Ceftriaxone Unavailable)

If ceftriaxone is not available, use cefixime 400 mg orally as a single dose PLUS azithromycin 1 g orally as a single dose, with mandatory test-of-cure at 1 week. 1, 3

Critical Limitations of Cefixime

  • Cefixime is significantly less effective than ceftriaxone, particularly for pharyngeal infections. 3
  • Rising cefixime MICs have resulted in declining effectiveness for urogenital gonorrhea treatment. 1
  • Oral cephalosporins are no longer first-line agents due to documented treatment failures in Europe. 4
  • Test-of-cure is mandatory at 1 week when using cefixime. 1, 3

Severe Cephalosporin Allergy

For patients with severe cephalosporin allergy, use azithromycin 2 g orally as a single dose, with mandatory test-of-cure at 1 week. 1, 3

Important Caveats

  • This regimen has lower efficacy (only 93% cure rate) compared to ceftriaxone-based therapy. 1, 5
  • High gastrointestinal side effects occur with azithromycin 2 g (35.3% of patients experience GI symptoms, with 2.9% severe). 5
  • Never use azithromycin 1 g alone for gonorrhea treatment—it is insufficient with only 93% efficacy. 1

Alternative for Severe Allergy

  • Gentamicin 240 mg IM single dose PLUS azithromycin 2 g orally single dose achieved 100% cure rate in clinical trials. 1, 6
  • However, gentamicin has poor pharyngeal efficacy (only 20% cure rate in one study). 1

Site-Specific Considerations

Pharyngeal Gonorrhea

Pharyngeal gonorrhea is significantly more difficult to eradicate than urogenital or anorectal infections, and ceftriaxone is the only reliably effective treatment. 1, 3

  • Ceftriaxone has superior efficacy for pharyngeal infections compared to all alternative treatments. 1
  • Spectinomycin has only 52% efficacy for pharyngeal infections and should be avoided. 1
  • Most ceftriaxone treatment failures involve the pharynx, not urogenital sites. 1

Special Populations

Pregnant Women

Use ceftriaxone 500 mg IM plus azithromycin 1 g orally in pregnant women. 1, 3

  • Never use quinolones or tetracyclines in pregnancy—they are absolutely contraindicated. 1, 3
  • Doxycycline is contraindicated in pregnancy, nursing women, and children under 8 years. 1

Men Who Have Sex with Men (MSM)

Ceftriaxone is the only recommended treatment for MSM due to higher prevalence of resistant strains. 1, 3

  • Never use quinolones for infections in MSM. 1
  • Do not use patient-delivered partner therapy in MSM due to high risk of undiagnosed coexisting STDs or HIV. 1

Neonates

  • Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy. 7
  • Ceftriaxone is contraindicated in premature neonates and in neonates ≤28 days requiring calcium-containing IV solutions. 7

Critical Pitfalls to Avoid

Fluoroquinolones Are Obsolete

Never use fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment due to widespread resistance. 1, 8

  • Despite historical effectiveness (99.8% cure rate in 1998), quinolones are no longer recommended as of 2007. 4, 1

Monotherapy Is Insufficient

  • Never use azithromycin 1 g alone—insufficient efficacy at only 93%. 1
  • Never use ceftriaxone alone without addressing potential chlamydial co-infection. 1

Partner Management

All sex partners from the preceding 60 days must be evaluated and treated. 1, 3

  • If the patient's last sexual contact was >60 days before symptom onset or diagnosis, treat the most recent partner. 3
  • Partners should receive the same dual therapy regimen for both gonorrhea and chlamydia. 1
  • Patients must avoid sexual intercourse until therapy is completed and both they and their partners are asymptomatic. 1
  • Consider expedited partner therapy with oral combination therapy (cefixime 400 mg plus azithromycin 1 g) if partners cannot be linked to timely evaluation. 1, 3

Follow-Up and Test-of-Cure Requirements

Routine Follow-Up

  • Patients treated with recommended ceftriaxone-based regimens do not need routine test-of-cure unless symptoms persist. 1
  • Consider retesting all patients 3 months after treatment due to high risk of reinfection. 1

Mandatory Test-of-Cure Situations

Test-of-cure at 1 week is mandatory for:

  • Patients receiving cefixime-based regimens 1, 3
  • Patients receiving azithromycin monotherapy 1
  • Patients with persistent symptoms after treatment 1

If Symptoms Persist

  • Obtain culture with antimicrobial susceptibility testing immediately. 1, 3
  • If nucleic acid amplification testing is positive at follow-up, confirm with culture. 1
  • All positive cultures should undergo phenotypic antimicrobial susceptibility testing. 1

Treatment Failure Management

If treatment failure occurs, take immediate action:

  • Obtain specimens for culture and antimicrobial susceptibility testing immediately. 1
  • Report the case to local public health officials within 24 hours. 1
  • Consult an infectious disease specialist. 1

Salvage Regimens for Treatment Failure

Recommended salvage regimens include: 1

  • Gentamicin 240 mg IM PLUS azithromycin 2 g orally (single dose)
  • Ertapenem 1 g IM for 3 days
  • Spectinomycin 2 g IM PLUS azithromycin 2 g orally (avoid for pharyngeal infections)

Concurrent Testing Requirements

Screen for syphilis with serology at the time of gonorrhea diagnosis. 3

  • Co-testing for HIV should also be performed given the facilitation of HIV transmission by gonorrhea. 4, 2

References

Guideline

Gonorrhea Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.

MMWR. Morbidity and mortality weekly report, 2020

Guideline

Gonorrhea Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014

Research

Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea.

Methods in molecular biology (Clifton, N.J.), 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.